Mind Medicine Inc (MNMD) Performance and Fundamentals Dashboard tells a completely different story

With 1.2 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.61 million shares. The 52-week range on MNMD shows that it touched its highest point at $10.44 and its lowest point at $4.70 during that stretch. It currently has a 1-year price target of $24.50. Beta for the stock currently stands at 2.90.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MNMD was down-trending over the past week, with a drop of -1.97%, but this was up by 32.11% over a month. Three-month performance dropped to -27.98% while six-month performance rose 6.60%. The stock lost -29.93% in the past year, while it has lost -7.18% so far this year. A look at the trailing 12-month EPS for MNMD yields -1.91 with Next year EPS estimates of -1.66. For the next quarter, that number is -0.37. This implies an EPS growth rate of 0.47% for this year and -8.45% for next year. EPS is expected to grow by 12.79% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 12.11%.

Float and Shares Shorts:

At present, 75.51 million MNMD shares are outstanding with a float of 72.71 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MNMD since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.29502 being high and -$1.5595 being low. For MNMD, this leads to a yearly average estimate of -$1.43182.